bluuebunny/crossref_metadata_2025_split huggingface dataset:
Impact of care at comprehensive cancer centers on outcome: Results from a population‐based study
Authors: Wolfson Julie A. , Sun Can‐Lan , Wyatt Laura P. , Hurria Arti , Bhatia Smita 
Published: July 2015

BACKGROUNDRigorous processes ensure quality of research and clinical care at National Cancer Institute‐designated comprehensive cancer centers (NCICCCs). Unmeasurable elements of structure and process of cancer care delivery warrant evaluation. To the authors' knowledge, the impact of NCICCC care on survival and access to NCICCCs for vulnerable subpopulations remain unstudied.METHODSThe current study's population‐based cohort of 69,579 patients had newly diagnosed adult‐onset (aged 22‐65 years) cancers reported to the Los Angeles County cancer registry between 1998 and 2008. Geographic information systems were used for geospatial analysis.RESULTSWith regard to overall survival across multiple diagnoses, patients not receiving their first planned treatment at NCICCCs experienced poorer outcomes compared with those treated at NCICCCs; differences persisted on multivariable analyses after adjusting for clinical and sociodemographic factors (hepatobiliary: hazard ratio [HR], 1.5; 95% confidence interval [95% CI], 1.4‐1.7 [P<.001]; lung: HR, 1.4; 95% CI, 1.3‐1.6 [P<.001]; pancreatic: HR, 1.5; 95% CI, 1.3‐1.7 [P<.001]; gastric: HR, 1.3; 95% CI, 1.1‐1.7 [P = .01]; breast: HR, 1.3; 95% CI, 1.1‐1.5 [P<.001]; and colorectal: HR, 1.2; 95% CI, 1.0‐1.4 [P = .05]). With regard to barriers to care, multivariable analyses revealed that a lower likelihood of treatment at NCICCCs was associated with race/ethnicity (African‐American: OR range across diagnoses: 0.4‐0.7 [P<.03]; Hispanic: OR range, 0.5‐0.7 [P<.04]); lack of private insurance (public: OR range, 0.6‐0.8 [P<.004]; uninsured: OR range, 0.1‐0.5 [P<.04]); less than high socioeconomic status (high‐middle: OR range, 0.4‐0.7 [P<.02]; middle: OR range, 0.3‐0.5 [P<.001]; and low: OR range, 0.2‐0.6 [P<.01]), and residing >9 miles from the nearest NCICCC (OR range, 0.5‐0.7 [P<.02]).CONCLUSIONSAmong individuals aged 22 to 65 years residing in Los Angeles County with newly diagnosed adult‐onset cancer, those who were treated at NCICCCs experienced superior survival compared with those treated at non‐NCICCC facilities. Barriers to care at NCICCCs included race/ethnicity, insurance, socioeconomic status, and distance to an NCICCC. Cancer 2015;121:3885–3893. © 2015 American Cancer Society.
Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
Authors: Menzies Alexander M. , Wilmott James S. , Drummond Martin , Lo Serigne , Lyle Megan , Chan Matthew M. K. , Thompson John F. , Guminski Alex , Carlino Matteo S. , Scolyer Richard A. , Kefford Richard F. , Long Georgina V. 
Published: July 2015

BACKGROUNDThe degree of response and the duration of survival of patients treated with mitogen‐activated protein kinase (MAPK) inhibitors are highly variable. Whether baseline clinicopathologic factors can predict the clinical course with treatment is largely unknown.METHODSFor 142 consecutive immunotherapy‐ and MAPK inhibitor–naive patients with BRAF‐mutant metastatic melanoma who were treated during clinical trials with BRAF inhibitors (n = 111) or a combination of dabrafenib and trametinib (n = 31), clinicopathologic factors were correlated with the response to MAPK inhibitors and survival.RESULTSThe median follow‐up was 15.7 months (range, 0.6‐60.5 months). The 2‐, 3‐, and 4‐year overall survival (OS) rates were 43%, 24%, and 24%, respectively. A multivariate analysis demonstrated that the only clinicopathologic factors associated with longer progression‐free survival (PFS) and OS were female sex and a normal pretreatment serum lactate dehydrogenase (LDH) level. The BRAF V600E genotype and an absence of primary melanoma ulceration were also independently associated with longer PFS but not OS. The median OS was 23.5 months for patients with normal LDH levels and 7.3 months for those with elevated LDH levels (hazard ratio, 0.31; P < .001). Complete responders had the best survival, but disease progression still occurred in 2 of 7 patients.CONCLUSIONSLong‐term survival occurs for a minority of patients receiving MAPK inhibitor treatment alone. Sex, serum LDH, BRAF genotype, and primary melanoma ulceration status are independent factors associated with treatment outcomes. Patients with a complete response to treatment have the best survival, but relapses still occur. Cancer 2015;121:3826–3835. © 2015 American Cancer Society.
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Authors: Yilmaz Musa , Lahoti Amit , O'Brien Susan , Nogueras‐González Graciela M. , Burger Jan , Ferrajoli Alessandra , Borthakur Gautam , Ravandi Farhad , Pierce Sherry , Jabbour Elias , Kantarjian Hagop , Cortes Jorge E. 
Published: July 2015

BACKGROUNDChronic use of tyrosine kinase inhibitors (TKIs) may lead to previously unrecognized adverse events. This study evaluated the incidence of acute kidney injury (AKI) and chronic kidney disease (CKD) in chronic‐phase (CP) chronic myeloid leukemia (CML) patients treated with imatinib, dasatinib, and nilotinib.METHODSFour hundred sixty‐eight newly diagnosed CP CML patients treated with TKIs were analyzed. The molecular and cytogenetic response data, creatinine, and glomerular filtration rate (GFR) were followed from the start of therapy to the last follow‐up (median, 52 months). GFR was estimated with the Modification of Diet in Renal Disease equation.RESULTSNineteen patients (4%) had TKI‐associated AKI. Imatinib was associated with a higher incidence of AKI in comparison with dasatinib and nilotinib (P = .014). Fifty‐eight patients (14%) developed CKD while they were receiving a TKI; 49 of these patients (84%) did so while they were being treated with imatinib (P < .001). Besides imatinib, age, a history of hypertension, and diabetes mellitus were also associated with the development of CKD. In patients with no CKD at the baseline, imatinib was shown to reduce GFR over time. Interestingly, imatinib did not cause a significant decline in the GFRs of patients with a history of CKD. Imatinib, dasatinib, and nilotinib increased the mean GFR after 3 months of treatment, and nilotinib led with the most significant increase (P < .001). AKI or CKD had no significant impact on overall cytogenetic and molecular response rates or survival.CONCLUSIONSThe administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted. Cancer 2015;121:3894–3904. © 2015 American Cancer Society.
Symptom profiles in children with advanced cancer: Patient, family caregiver, and oncologist ratings
Authors: Zhukovsky Donna S. , Rozmus Cathy L. , Robert Rhonda S. , Bruera Eduardo , Wells Robert J. , Chisholm Gary B. , Allo Julio A. , Cohen Marlene Z. 
Published: July 2015

BACKGROUNDSystematic symptom assessment is not routinely performed in pediatric oncology. The objectives of the current study were to characterize the symptoms of pediatric oncology outpatients and evaluate agreement between patient and proxy reports and the association between children's ratings and oncologists' treatment recommendations.METHODSTwo versions of the pediatric Memorial Symptom Assessment Scale (pMSAS) were translated into Spanish. An age‐appropriate and language‐appropriate pMSAS was administered independently before visits to the oncologist to patients and family caregivers (caregivers) and after visits to consenting oncologists. Statistical analysis included Spearman correlation coefficients and weighted kappa values.RESULTSEnglish and Spanish results were similar and were combined. A total of 60 children and their caregivers completed the pMSAS. The children had a median age of 10 years (range, 7‐18 years); approximately 62% were male and 33% were Spanish‐speaking. Fourteen oncologists completed the pMSAS for 25 patients. Nine patients (15%) had no symptoms and 38 patients (63%) reported ≥2 symptoms. The most common symptoms were fatigue (12 patients; 40%) and itch (9 patients; 30%) for the younger children and pain (15 patients; 50%) and lack of energy (13 patients; 45%) among the older children. Total and subscale score agreement varied by proxy type and subscale, ranging from fair to good for most comparisons. Agreement for individual symptoms between the patient and proxy ranged from a kappa of −0.30 (95% confidence interval, −0.43 to −0.01) to 0.91 (95% confidence interval, 0.75 to 1.00). Three of 51 symptomatic patients (6%) had treatment recommendations documented in the electronic health record.CONCLUSIONSSymptoms are common and cross several functional domains. Proxy and child reports are often not congruent, possibly explaining apparent undertreatment among this group of patients. Cancer 2015;121:4080–4087. © 2015 American Cancer Society.
Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia
Authors: Short Nicholas J. , Keating Michael J. , Wierda William G. , Faderl Stefan , Ferrajoli Alessandra , Estrov Zeev , Smith Susan C. , O'Brien Susan M. 
Published: July 2015

BACKGROUNDFludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patients with relapsed CLL, a dose‐intensified rituximab regimen increases response rates in comparison with standard‐dose rituximab. It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL.METHODSA single‐arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple‐dose rituximab (FCR3) in 65 patients with previously untreated CLL. The results were compared with those for a historical cohort treated with FCR.RESULTSThe overall response rate to FCR3 was 97%, with 75% of the patients achieving a complete remission. Minimal residual disease negativity was achieved for 62% of the patients according to flow cytometry. The median time to progression (TTP) was 81 months, and the median overall survival (OS) was not reached, with 58% of the patients still alive at a median survivor follow‐up of 9.7 years. Grade 3 or 4 neutropenia, grade 3 or 4 thrombocytopenia, and major infections were observed with 45%, 5%, and 1.9% of the FCR3 courses, respectively. Therapy‐related myelodysplastic syndrome (t‐MDS) or therapy‐related acute myelogenous leukemia (t‐AML) developed in 7 patients (11%; P < .01 vs the historical FCR cohort).CONCLUSIONSIn patients with previously untreated CLL, FCR3 resulted in response rates, TTP, and OS similar to those of a historical cohort of patients treated with FCR. FCR3 was associated with an increased incidence of t‐MDS/t‐AML. Cancer 2015;121:3869–3876. © 2015 American Cancer Society.
Scalable multi‐dimensional RNN query processing
Authors: Ji Changqing , Qu Wenyu , Li Zhiyang , Xu Yujie , Li Yuanyuan , Wu Junfeng 
Published: July 2015

SummaryReverse nearest neighbor (RNN) queries are the complimentary problem and particular interest in the past few years, such as location‐based services, profile‐based marketing, resource allocation, and traffic monitoring system. The one major drawback for the existing RNN is that it has inherent sequential nature and uses in‐memory algorithm, which limits its applicability to large‐scale spatial data queries. This paper proposes scalable algorithms for RNN queries in a distributed environment. Firstly, we investigate the Basic‐scalable reverse nearest neighbor (SRNN) initialization query method based on the inverted grid index. Secondly, two optimization methods Lazy‐SRNN and Eager‐SRNN are proposed to effectively process scalable multi‐dimensional RNN queries. Among them, Lazy‐SRNN prunes the search space when all RNN objects are discovered in one pass; Eager‐SRNN attempts to prune spatial objects incrementally as soon as they are visited. In addition, the SRNN algorithm is proved to be the first attempt for the exact scalable RNN algorithms in a distributed environment on multi‐dimensional data sets. We show in an extensive experimental evaluation on real‐world and synthetic data the scalability and the performance of our novel approach. Copyright © 2015 John Wiley & Sons, Ltd.
Secure routing and resource allocation based on game theory in cooperative cognitive radio networks
Authors: Fang He , Xu Li , Xiao Liang 
Published: July 2015

SummaryThe era of big data is here now, and spectrum resources are increasingly scarce in heterogeneous network environment. The spectrum efficiency and secure transmission of big data are important issues. Cognitive radio has been proposed to address the issue of spectrum efficiency, and is a hot topic in the literatures. In multi‐hop cooperative cognitive radio networks (CCRNs), secondary users need the primary users' authorization to be relays. Most existing centralized route selection schemes ignore the energy allocation, and thus are inefficient. Moreover, the incomplete of information in multi‐hop network leads to many difficulties in cooperation. Inspired by the game theory, a novel strategy is proposed in this paper to defend against insider attacks based on trust. This strategy is denoted as secure routing and resource allocation based on game theory in CCRNs (SRGC). With a reputation updating process and distributed learning algorithm, the proposed strategy can find a ‘best’ route, which is relatively safe for each primary transmitter, and at the same time fully utilizes the spectrum and energy. Using NS2, simulations indicate that SRGC can well fit into CCRNs, improve the network performance and defend against the routing disruption attacks. Compared with other schemes, the SRGC results in a performance with better adaptability to the distributed environment. Moreover, SRGC can maximize the average throughput and minimize the data drop ratios. Copyright © 2015 John Wiley & Sons, Ltd.
Trust‐based security‐level evaluation method for dynamic service‐oriented environments
Authors: Kołaczek Grzegorz , Juszczyszyn Krzysztof , Świątek Paweł , Grzech Adam , Schauer Patryk , Stelmach Paweł , Falas Łukasz 
Published: July 2015

SummaryA method of decision‐making in security‐level estimation process of service‐based applications in future Internet architecture is proposed. We demonstrate how distributed services can be composed to form an application run within the next‐generation network infrastructure and their security level may be assessed. Our approach is illustrated by the experiments carried on exemplary application (virtual laboratory online lab, using future Internet IPv6 QoS architecture), in which our method was evaluated against two types of attacks observed with the use of traffic anomaly detection methods. Copyright © 2015 John Wiley & Sons, Ltd.
An energy‐aware performance analysis of SWIMM: Smith–Waterman implementation on Intel's Multicore and Manycore architectures
Authors: Rucci Enzo , García Carlos , Botella Guillermo , De Giusti Armando , Naiouf Marcelo , Prieto‐Matías Manuel 
Published: July 2015

SummaryAlignment is essential in many areas such as biological, chemical and criminal forensics. The well‐known Smith–Waterman (SW) algorithm is able to retrieve the optimal local alignment with quadratic time and space complexity. There are several implementations that take advantage of computing parallelization, such as manycores, FPGAs or GPUs, in order to reduce the alignment effort. In this research, we adapt, develop and tune the SW algorithm named SWIMM on a heterogeneous platform based on Intel's Xeon and Xeon Phi coprocessor. SWIMM is a free tool available in a public git repository https://github.com/enzorucci/SWIMM. We efficiently exploit data and thread‐level parallelism, reaching up to 380 GCUPS on heterogeneous architecture, 350 GCUPS for the isolated Xeon and 50 GCUPS on Xeon Phi. Despite the heterogeneous implementation obtaining the best performance, it is also the most energy‐demanding. In fact, we also present a trade‐off analysis between performance and power consumption. The greenest configuration is based on an isolated multicore system that exploits AVX2 instruction set architecture reaching 1.5 GCUPS/Watts. Copyright © 2015 John Wiley & Sons, Ltd.
Estimation of Lattice Enthalpies of Ionic Liquids Supported by Hirshfeld Analysis
Authors: Preiss Ulrich P. , Zaitsau Dzmitry H. , Beichel Witali , Himmel Daniel , Higelin Alexander , Merz Klaus , Caesar Niklas , Verevkin Sergey P. 
Published: July 2015

AbstractNew measurements of vaporization enthalpies for 15 1:1 ionic liquids are performed by using a quartz‐crystal microbalance. Collection and analysis of 33 available crystal structures of organic salts, which comprise 13 different cations and 12 anions, is performed. Their dissociation lattice enthalpies are calculated by a combination of experimental and quantum chemical quantities and are divided into the relaxation and Coulomb components to give an insight into elusive short‐range interaction enthalpies. An empirical equation is developed, based on interaction‐specific Hirshfeld surfaces and solvation enthalpies, which enables the estimation of the lattice enthalpy by using only the crystal‐structure data.
Rational Design of a Hierarchical Tin Dendrite Electrode for Efficient Electrochemical Reduction of CO2
Authors: Won Da Hye , Choi Chang Hyuck , Chung Jaehoon , Chung Min Wook , Kim Eun‐Hee , Woo Seong Ihl 
Published: July 2015

AbstractCatalysis is a key technology for the synthesis of renewable fuels through electrochemical reduction of CO2. However, successful CO2 reduction still suffers from the lack of affordable catalyst design and understanding the factors governing catalysis. Herein, we demonstrate that the CO2 conversion selectivity on Sn (or SnOx/Sn) electrodes is correlated to the native oxygen content at the subsurface. Electrochemical analyses show that the reduced Sn electrode with abundant oxygen species effectively stabilizes a CO2.− intermediate rather than the clean Sn surface, and consequently results in enhanced formate production in the CO2 reduction. Based on this design strategy, a hierarchical Sn dendrite electrode with high oxygen content, consisting of a multi‐branched conifer‐like structure with an enlarged surface area, was synthesized. The electrode exhibits a superior formate production rate (228.6 μmol h−1 cm−2) at −1.36 VRHE without any considerable catalytic degradation over 18 h of operation.
Novel full‐spectral flow cytometry with multiple spectrally‐adjacent fluorescent proteins and fluorochromes and visualization of in vivo cellular movement
Authors: Futamura Koji , Sekino Masashi , Hata Akihiro , Ikebuchi Ryoyo , Nakanishi Yasutaka , Egawa Gyohei , Kabashima Kenji , Watanabe Takeshi , Furuki Motohiro , Tomura Michio 
Published: July 2015

AbstractFlow cytometric analysis with multicolor fluoroprobes is an essential method for detecting biological signatures of cells. Here, we present a new full‐spectral flow cytometer (spectral‐FCM). Unlike conventional flow cytometer, this spectral‐FCM acquires the emitted fluorescence for all probes across the full‐spectrum from each cell with 32 channels sequential PMT unit after dispersion with prism, and extracts the signals of each fluoroprobe based on the spectral shape of each fluoroprobe using unique algorithm in high speed, high sensitive, accurate, automatic and real‐time. The spectral‐FCM detects the continuous changes in emission spectra from green to red of the photoconvertible protein, KikGR with high‐spectral resolution and separates spectrally‐adjacent fluoroprobes, such as FITC (Emission peak (Em) 519 nm) and EGFP (Em 507 nm). Moreover, the spectral‐FCM can measure and subtract autofluorescence of each cell providing increased signal‐to‐noise ratios and improved resolution of dim samples, which leads to a transformative technology for investigation of single cell state and function. These advances make it possible to perform 11‐color fluorescence analysis to visualize movement of multilinage immune cells by using KikGR‐expressing mice. Thus, the novel spectral flow cytometry improves the combinational use of spectrally‐adjacent various FPs and multicolor fluorochromes in metabolically active cell for the investigation of not only the immune system but also other research and clinical fields of use. © 2015 The Authors. Cytometry Part A Published by Wiley Periodicals, Inc. on behalf of ISAC
Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
Authors: Fraccarollo Daniela , Galuppo Paolo , Sieweke Jan‐Thorben , Napp L. Christian , Grobbecker Paul , Bauersachs Johann 
Published: July 2015

AbstractAimsThe selective mineralocorticoid receptor (MR) antagonist eplerenone given early in patients with acute myocardial infarction (MI) improves clinical outcome, whereas little is known about the effectiveness of early spironolactone therapy. We aimed to compare the ability of eplerenone and spironolactone to promote cardiac repair after experimental MI.Methods and resultsStarting immediately after coronary artery ligation, C57BL/6J mice were treated with placebo, eplerenone, or spironolactone. At 7 days, treatment with eplerenone or spironolactone reduced thinning and expansion of healing infarct and improved early left ventricular chamber enlargement. Remarkably, eplerenone therapy resulted in significantly greater improvement than spironolactone of left ventricular contractile function and relaxation, associated with a more considerable leftward and downward shift of the pressure volume curve. Seven‐day survival rate was significantly increased only in eplerenone treated mice. Moreover, eplerenone was superior to spironolactone in ameliorating neovessel formation in the injured myocardium. Optimized flow cytometry analysis of the monocyte differentiation marker Ly6C revealed predominant accumulation of Ly6Chigh monocytes/macrophages at the site of ischemic injury during the early inflammatory phase in placebo‐treated mice. In contrast, MR antagonism, especially by eplerenone, led to a skewing of the monocyte/macrophage population toward a higher frequency of healing promoting Ly6Clow cells.ConclusionThe MR antagonist eplerenone versus spironolactone showed superior efficacy during the acute MI phase with more beneficial effects on survival, early cardiac dilation, and functional decline. Modulation of monocyte maturation and enhanced infarct neovessel formation appears to play a pivotal role.
Biological Oxidation Reactions – Mechanisms and Design of New Catalysts
Authors: Browne Wesley R. , Nordlander Ebbe 
Published: July 2015

AbstractAn overview of the papers in this cluster issue is presented.
“Biological oxidation reactions utilising dioxygen, superoxide or hydrogen peroxide as oxidants are amongst the most ubiquitous of metal‐catalysed reactions in biology. Over the last four years, the COST action CM1003 ‘Biological Oxidation Reactions – Mechanisms and Design of New Catalysts’ has brought together over 150 researchers from over 18 European countries to exchange ideas and collaborate on answering key questions facing the field.”